Seoul Court Overturns Health Ministry's 14-Percent Price Cut On Novartis' Glivec
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Seoul's Administrative Court ruled in favor of Novartis and suspended the Korean health ministry's plan to cut the price of the Swiss-based company's leukemia drug Glivec (imatinib) by 14 percent beginning Sept. 15
You may also be interested in...
Seoul Court Maintains Stance Not To Raise Novartis' Glivec Price; Health Ministry May Appeal To Higher Court
SEOUL - In what appears to be a victory - at least for now - for multinational pharma companies in their fight against mounting calls for price cuts, a Seoul Administrative Court maintained its earlier stance and ruled that a court-ordered price cut for Novartis' Glivec (imatinib) goes against "fairness" and the purpose of the EU free trade agreement
Seoul Court Maintains Stance Not To Raise Novartis' Glivec Price; Health Ministry May Appeal To Higher Court
SEOUL - In what appears to be a victory - at least for now - for multinational pharma companies in their fight against mounting calls for price cuts, a Seoul Administrative Court maintained its earlier stance and ruled that a court-ordered price cut for Novartis' Glivec (imatinib) goes against "fairness" and the purpose of the EU free trade agreement
Seoul Court Maintains Stance Not To Raise Novartis' Glivec Price; Health Ministry May Appeal To Higher Court
A mandated price cut for imatinib goes against "fairness" and the purpose of the EU free trade agreement, the court said.